Literature DB >> 7904612

A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome.

S W Lamberts, W W de Herder, E P Krenning, J C Reubi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7904612     DOI： 10.1210/jcem.78.1.7904612

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  11 in total

Review 1.  The therapeutic value of somatostatin and its analogues.

Authors:  S Farooqi; J S Bevan; M C Sheppard; J A Wass
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

Review 2.  Endocrine paraneoplastic syndromes with special reference to the elderly.

Authors:  L Bollanti; G Riondino; F Strollo
Journal:  Endocrine       Date:  2001-03       Impact factor: 3.633

Review 3.  Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors.

Authors:  Wouter W de Herder; Steven W J Lamberts
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

Review 4.  Somatostatin analogue treatment of neuroendocrine tumours.

Authors:  W W de Herder; A J van der Lely; S W Lamberts
Journal:  Postgrad Med J       Date:  1996-07       Impact factor: 2.401

Review 5.  Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review.

Authors:  Andrea M Isidori; Emilia Sbardella; Maria Chiara Zatelli; Mara Boschetti; Giovanni Vitale; Annamaria Colao; Rosario Pivonello
Journal:  J Clin Endocrinol Metab       Date:  2015-09       Impact factor: 5.958

6.  Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells.

Authors:  Aura D Herrera-Martínez; Richard A Feelders; Wouter W de Herder; Justo P Castaño; María Ángeles Gálvez Moreno; Fadime Dogan; Rosanna van Dungen; Peter van Koetsveld; Leo J Hofland
Journal:  Horm Cancer       Date:  2019-05-18       Impact factor: 3.869

7.  Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion.

Authors:  C de Bruin; L J Hofland; L K Nieman; P M van Koetsveld; A M Waaijers; D M Sprij-Mooij; M van Essen; S W J Lamberts; W W de Herder; R A Feelders
Journal:  J Clin Endocrinol Metab       Date:  2011-11-16       Impact factor: 5.958

Review 8.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

9.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).

Authors:  John K Ramage; A Ahmed; J Ardill; N Bax; D J Breen; M E Caplin; P Corrie; J Davar; A H Davies; V Lewington; T Meyer; J Newell-Price; G Poston; N Reed; A Rockall; W Steward; R V Thakker; C Toubanakis; J Valle; C Verbeke; A B Grossman
Journal:  Gut       Date:  2011-11-03       Impact factor: 23.059

10.  Bright fluorescence monitoring system utilizing Zoanthus sp. green fluorescent protein (ZsGreen) for human G-protein-coupled receptor signaling in microbial yeast cells.

Authors:  Yasuyuki Nakamura; Jun Ishii; Akihiko Kondo
Journal:  PLoS One       Date:  2013-12-05       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.